A retrospective study of a novel 3-session rush venom immunotherapy protocol.

Autor:	McCarty ME; Division of Pulmonary, Allergy, Critical Care Medicine, and Sleep Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Fajt ML; Division of Pulmonary, Allergy, Critical Care Medicine, and Sleep Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Gershuni LS; Division of Pulmonary, Allergy, Critical Care Medicine, and Sleep Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania., Petrov AA; Division of Pulmonary, Allergy, Critical Care Medicine, and Sleep Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address: petrovaa@upmc.edu.
Jazyk:	angličtina
Zdroj:	Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [Ann Allergy Asthma Immunol] 2024 Oct; Vol. 133 (4), pp. 462-468. Date of Electronic Publication: 2024 Jul 18.
DOI:	10.1016/j.anai.2024.07.013
Abstrakt:	Background: Venom immunotherapy (VIT) is an effective treatment for life-threatening stinging-insect hypersensitivity. Rush VIT protocols allow patients to reach maintenance dosing faster, thus conferring protection sooner. The published protocols vary in dosing regimens, monitoring parameters, and safety profiles. Objective: To describe a novel 3-session outpatient rush VIT protocol with full therapeutic dosing achieved at the end of session 3. Methods: We conducted a retrospective chart review of adult patients treated with rush VIT in an outpatient university allergy/immunology clinic. Demographic and clinical data, including the type of sting reaction, the number of venom allergens, and any systemic reactions (SRs) during VIT, were analyzed. Results: Over a 14-year period, 55 patients (28 females and 27 males) with a median age of 47 years underwent our VIT protocol. A total of 46 patients (84%) tolerated the procedure without SR, and 53 (96%) attained full maintenance dosing. All reactions during rush were Brown anaphylaxis criteria grade 1 or 2. Although the most common venom allergy was yellow jacket, most patients had multiple venom allergies and received therapy with more than 1 venom. Furthermore, 10 patients were re-stung while on maintenance with only 1 patient having a mild SR. Conclusion: Our 3-session outpatient rush VIT protocol is effective and safe. Most patients had no SR and attained maintenance dosing. Compared with other 3-session rush protocols, our protocol requires non-invasive monitoring, and patients achieved monthly maintenance dosing immediately on completion. Competing Interests: Disclosures Dr Petrov has served on the advisory board for Genentech, CSL Behring, and Blueprint Medicines. The other authors have no conflicts of interest to declare. (Copyright © 2024 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu